<p>Bronte Capital Management Pty Ltd. 在最近向证券交易委员会提交的文件中表示，在第四季度将其在 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - 免费报告) 的持股增加了 11.1%。该公司在该季度购买了额外的 3,890 股后，持有该生物制药公司 38,864 股股票。Alnylam Pharmaceuticals 大约占 Bronte Capital Management Pty Ltd. 投资组合的 1.7%，使其成为该公司第 11 大持股。截止最近一个季度末，Bronte Capital Management Pty Ltd. 在 Alnylam Pharmaceuticals 的持股价值为 15,454,000 美元。</p>
<ul>
<li>Alnylam 股票飙升 65%：了解背后的原因</li>
</ul>
<p>其他对冲基金也买卖了该公司的股票。Mediolanum International Funds Ltd 在第三季度收购了价值 11,389,000 美元的 Alnylam Pharmaceuticals 新股份。Rakuten Investment Management Inc. 在第三季度收购了价值 14,205,000 美元的 Alnylam Pharmaceuticals 新股份。Cerity Partners LLC 在第三季度将其在 Alnylam Pharmaceuticals 的持股增加了 171.2%。Cerity Partners LLC 现在持有该生物制药公司 27,429 股股票，价值 12,507,000 美元，此前在该期间内购买了额外的 17,316 股。Campbell &amp; CO Investment Adviser LLC 在第三季度收购了价值 5,790,000 美元的 Alnylam Pharmaceuticals 新股份。最后，Perpetual Ltd 在第四季度收购了价值 2,004,000 美元的 Alnylam Pharmaceuticals 新股份。机构投资者和对冲基金持有该公司 92.97% 的股票。</p>
<h2>分析师评级升级与降级</h2>
<p>多位股票分析师对 ALNY 股票发布了报告。Weiss Ratings 在周一的报告中将 Alnylam Pharmaceuticals 的股票评级从 &#34;卖出 (d+)&#34; 上调至 &#34;持有 (c-)&#34;。Chardan Capital 在 3 月 25 日的报告中重申了 &#34;买入&#34; 评级，并设定了 425.00 美元的价格目标。巴克莱在 1 月 28 日的报告中开始覆盖 Alnylam Pharmaceuticals 的股票，设定了 &#34;增持&#34; 评级和 527.00 美元的价格目标。Wall Street Zen 在周六的报告中将 Alnylam Pharmaceuticals 的股票评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。最后，Canaccord Genuity Group 在 2 月 17 日的报告中将 Alnylam Pharmaceuticals 的股票价格目标从 415.00 美元上调至 429.00 美元，并给予该股票 &#34;买入&#34; 评级。一位分析师给予该股票 &#34;强烈买入&#34; 评级，十九位分析师给予 &#34;买入&#34; 评级，六位分析师给予 &#34;持有&#34; 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，平均价格目标为 471.96 美元。</p>
<ul>
<li>3 家生物技术巨头在行业反弹中蓄势待发</li>
</ul>
<p><strong>查看我们最新的 Alnylam Pharmaceuticals 股票分析</strong></p>
<h2>Alnylam Pharmaceuticals 的内部活动</h2>
<p>在其他新闻中，执行副总裁 Tolga Tanguler 于 3 月 2 日星期一出售了 1,598 股 Alnylam Pharmaceuticals 股票。该股票以平均价格 327.65 美元出售，总交易额为 523,584.70 美元。出售后，该执行副总裁直接持有该公司 36,606 股股票，价值 11,993,955.90 美元。此次交易使其持股减少了 4.18%。该交易已在向 SEC 提交的文件中披露，文件可在此链接查看。此外，内部人士 Melissa Mclaughlin 于 4 月 6 日星期一出售了 2,286 股 Alnylam Pharmaceuticals 股票。该股票以平均价格 330.42 美元出售，总价值为 755,340.12 美元。出售后，该内部人士持有该公司 9,443 股股票，价值 3,120,156.06 美元。此次交易使其持股减少了 19.49%。该出售的披露信息可在 SEC 文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。出售是为了支付与股权奖励归属相关的税款。在过去的九十天里，内部人士出售了价值 12,370,696 美元的 38,656 股公司股票。公司内部人士持有 0.86% 的股票。</p>
<h2>Alnylam Pharmaceuticals 价格表现</h2>
<ul>
<li>Argenx 的 28% 激增及其有前景的产品提升了投资者信心</li>
</ul>
<p>ALNY 周三以 301.11 美元开盘。该公司的债务与股本比率为 0.94，流动比率为 3.13，速动比率为 3.06。该公司的市值为 402 亿美元，市盈率为 82.27，贝塔值为 0.31。该公司的 50 日移动平均价格为 319.41 美元，200 日移动平均价格为 374.99 美元。Alnylam Pharmaceuticals, Inc. 的一年低点为 245.96 美元，一年高点为 495.55 美元。</p>
<p>Alnylam Pharmaceuticals (NASDAQ:ALNY - 获取免费报告) 最近于 4 月 30 日星期四发布了其财报。该生物制药公司报告该季度每股收益为 1.99 美元，超出分析师共识预期的 0.87 美元，超出幅度为 1.12 美元。该公司该季度的收入为 11.7 亿美元，而分析师预期为 11.2 亿美元。Alnylam Pharmaceuticals 的股本回报率为 85.76%，净利润率为 11.72%。该公司的季度收入同比增长 96.4%。在去年同期，该公司每股收益为 -0.44 美元。整体来看，分析师预计 Alnylam Pharmaceuticals, Inc. 在当前财年将发布 6.78 美元的每股收益。</p>
<h2>Alnylam Pharmaceuticals 简介</h2>
<p>(免费报告)</p>
<p>阿尼拉姆制药公司（Alnylam Pharmaceuticals, Inc.）纳斯达克股票代码：ALNY，是一家专注于 RNA 干扰（RNAi）治疗药物的发现、开发和商业化的生物制药公司。该公司成立的目的是将 RNAi 的科学发现转化为新药物，阿尼拉姆利用小干扰 RNA（siRNA）技术来沉默致病基因。公司开发的疗法旨在通过针对一系列罕见和更普遍疾病的潜在遗传驱动因素，提供持久的疾病修正。</p>
<p>阿尼拉姆已将多种基于 siRNA 的产品推进至商业化，最初使用脂质纳米颗粒递送，最近则采用 GalNAc 结合化学以实现针对肝脏的靶向递送，并通过皮下给药。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过阿尼拉姆制药</li>
</ul>
<p><strong>想看看其他对 ALNY 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取阿尼拉姆制药公司（NASDAQ:ALNY - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在阿尼拉姆制药吗？</h2>
<p>在考虑阿尼拉姆制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而阿尼拉姆制药并不在名单上。</p>
<p>虽然阿尼拉姆制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

阿里拉姆制药

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

美国制药 ETF - iShares

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

<p>Bronte Capital Management Pty Ltd. 在第四季度将其在阿里拉姆制药（Alnylam Pharmaceuticals, Inc.）的持股增加了 11.1%，目前持有 38,864 股，价值 1,545 万美元。其他对冲基金也投资了阿里拉姆，目前该公司 92.97% 的股份由机构投资者持有。分析师对该股票给予了 “适度买入” 的共识评级，平均目标价为 471.96 美元。最近有内部人士出售股票以支付税务义务。阿里拉姆的股票表现显示市值为 402 亿美元，市盈率为 82.27</p>

<p>Bronte Capital Management Pty Ltd. boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 38,864 shares of the biopharmaceutical company's stock after purchasing an additional 3,890 shares during the quarter. Alnylam Pharmaceuticals comprises approximately 1.7% of Bronte Capital Management Pty Ltd.'s investment portfolio, making the stock its 11th largest holding. Bronte Capital Management Pty Ltd.'s holdings in Alnylam Pharmaceuticals were worth $15,454,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Bronte Capital Management Pty Ltd. 在最近向证券交易委员会提交的文件中表示，在第四季度将其在 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - 免费报告) 的持股增加了 11.1%。该公司在该季度购买了额外的 3,890 股后，持有该生物制药公司 38,864 股股票。Alnylam Pharmaceuticals 大约占 Bronte Capital Management Pty Ltd. 投资组合的 1.7%，使其成为该公司第 11 大持股。截止最近一个季度末，Bronte Capital Management Pty Ltd. 在 Alnylam Pharmaceuticals 的持股价值为 15,454,000 美元。</p>
</div><ul>
<li>Alnylam Stock Soars 65%: Find Out What’s Behind the Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>Alnylam 股票飙升 65%：了解背后的原因</li>
</ul>
</div><p>Other hedge funds have also bought and sold shares of the company. Mediolanum International Funds Ltd acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $11,389,000. Rakuten Investment Management Inc. acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $14,205,000. Cerity Partners LLC grew its position in Alnylam Pharmaceuticals by 171.2% in the 3rd quarter. Cerity Partners LLC now owns 27,429 shares of the biopharmaceutical company's stock valued at $12,507,000 after purchasing an additional 17,316 shares during the period. Campbell &amp; CO Investment Adviser LLC acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $5,790,000. Finally, Perpetual Ltd acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $2,004,000. Institutional investors and hedge funds own 92.97% of the company's stock.</p>
<div class="lb-trans"><p>其他对冲基金也买卖了该公司的股票。Mediolanum International Funds Ltd 在第三季度收购了价值 11,389,000 美元的 Alnylam Pharmaceuticals 新股份。Rakuten Investment Management Inc. 在第三季度收购了价值 14,205,000 美元的 Alnylam Pharmaceuticals 新股份。Cerity Partners LLC 在第三季度将其在 Alnylam Pharmaceuticals 的持股增加了 171.2%。Cerity Partners LLC 现在持有该生物制药公司 27,429 股股票，价值 12,507,000 美元，此前在该期间内购买了额外的 17,316 股。Campbell &amp; CO Investment Adviser LLC 在第三季度收购了价值 5,790,000 美元的 Alnylam Pharmaceuticals 新股份。最后，Perpetual Ltd 在第四季度收购了价值 2,004,000 美元的 Alnylam Pharmaceuticals 新股份。机构投资者和对冲基金持有该公司 92.97% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级升级与降级</h2>
</div><p>A number of equities analysts have issued reports on ALNY shares. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a &#34;sell (d+)&#34; rating to a &#34;hold (c-)&#34; rating in a report on Monday. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Barclays started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 28th. They set an &#34;overweight&#34; rating and a $527.00 price objective on the stock. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday. Finally, Canaccord Genuity Group lifted their price objective on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $471.96.</p>
<div class="lb-trans"><p>多位股票分析师对 ALNY 股票发布了报告。Weiss Ratings 在周一的报告中将 Alnylam Pharmaceuticals 的股票评级从 &#34;卖出 (d+)&#34; 上调至 &#34;持有 (c-)&#34;。Chardan Capital 在 3 月 25 日的报告中重申了 &#34;买入&#34; 评级，并设定了 425.00 美元的价格目标。巴克莱在 1 月 28 日的报告中开始覆盖 Alnylam Pharmaceuticals 的股票，设定了 &#34;增持&#34; 评级和 527.00 美元的价格目标。Wall Street Zen 在周六的报告中将 Alnylam Pharmaceuticals 的股票评级从 &#34;持有&#34; 上调至 &#34;买入&#34;。最后，Canaccord Genuity Group 在 2 月 17 日的报告中将 Alnylam Pharmaceuticals 的股票价格目标从 415.00 美元上调至 429.00 美元，并给予该股票 &#34;买入&#34; 评级。一位分析师给予该股票 &#34;强烈买入&#34; 评级，十九位分析师给予 &#34;买入&#34; 评级，六位分析师给予 &#34;持有&#34; 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 &#34;适度买入&#34;，平均价格目标为 471.96 美元。</p>
</div><ul>
<li>3 biotech powerhouses poised to thrive amid sector rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家生物技术巨头在行业反弹中蓄势待发</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Analysis on Alnylam Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Alnylam Pharmaceuticals 股票分析</strong></p>
</div><h2>Insider Activity at Alnylam Pharmaceuticals</h2>
<div class="lb-trans"><h2>Alnylam Pharmaceuticals 的内部活动</h2>
</div><p>In other news, EVP Tolga Tanguler sold 1,598 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $523,584.70. Following the sale, the executive vice president directly owned 36,606 shares in the company, valued at $11,993,955.90. The trade was a 4.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the sale, the insider owned 9,443 shares in the company, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 38,656 shares of company stock worth $12,370,696. 0.86% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Tolga Tanguler 于 3 月 2 日星期一出售了 1,598 股 Alnylam Pharmaceuticals 股票。该股票以平均价格 327.65 美元出售，总交易额为 523,584.70 美元。出售后，该执行副总裁直接持有该公司 36,606 股股票，价值 11,993,955.90 美元。此次交易使其持股减少了 4.18%。该交易已在向 SEC 提交的文件中披露，文件可在此链接查看。此外，内部人士 Melissa Mclaughlin 于 4 月 6 日星期一出售了 2,286 股 Alnylam Pharmaceuticals 股票。该股票以平均价格 330.42 美元出售，总价值为 755,340.12 美元。出售后，该内部人士持有该公司 9,443 股股票，价值 3,120,156.06 美元。此次交易使其持股减少了 19.49%。该出售的披露信息可在 SEC 文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。出售是为了支付与股权奖励归属相关的税款。在过去的九十天里，内部人士出售了价值 12,370,696 美元的 38,656 股公司股票。公司内部人士持有 0.86% 的股票。</p>
</div><h2>Alnylam Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Alnylam Pharmaceuticals 价格表现</h2>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 激增及其有前景的产品提升了投资者信心</li>
</ul>
</div><p>ALNY opened at $301.11 on Wednesday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The company has a market capitalization of $40.20 billion, a price-to-earnings ratio of 82.27 and a beta of 0.31. The firm's fifty day moving average price is $319.41 and its two-hundred day moving average price is $374.99. Alnylam Pharmaceuticals, Inc. has a 1 year low of $245.96 and a 1 year high of $495.55.</p>
<div class="lb-trans"><p>ALNY 周三以 301.11 美元开盘。该公司的债务与股本比率为 0.94，流动比率为 3.13，速动比率为 3.06。该公司的市值为 402 亿美元，市盈率为 82.27，贝塔值为 0.31。该公司的 50 日移动平均价格为 319.41 美元，200 日移动平均价格为 374.99 美元。Alnylam Pharmaceuticals, Inc. 的一年低点为 245.96 美元，一年高点为 495.55 美元。</p>
</div><p>Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping analysts' consensus estimates of $0.87 by $1.12. The company had revenue of $1.17 billion for the quarter, compared to analysts' expectations of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business's revenue for the quarter was up 96.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.44) EPS. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.78 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Alnylam Pharmaceuticals (NASDAQ:ALNY - 获取免费报告) 最近于 4 月 30 日星期四发布了其财报。该生物制药公司报告该季度每股收益为 1.99 美元，超出分析师共识预期的 0.87 美元，超出幅度为 1.12 美元。该公司该季度的收入为 11.7 亿美元，而分析师预期为 11.2 亿美元。Alnylam Pharmaceuticals 的股本回报率为 85.76%，净利润率为 11.72%。该公司的季度收入同比增长 96.4%。在去年同期，该公司每股收益为 -0.44 美元。整体来看，分析师预计 Alnylam Pharmaceuticals, Inc. 在当前财年将发布 6.78 美元的每股收益。</p>
</div><h2>Alnylam Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>Alnylam Pharmaceuticals 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.</p>
<div class="lb-trans"><p>阿尼拉姆制药公司（Alnylam Pharmaceuticals, Inc.）纳斯达克股票代码：ALNY，是一家专注于 RNA 干扰（RNAi）治疗药物的发现、开发和商业化的生物制药公司。该公司成立的目的是将 RNAi 的科学发现转化为新药物，阿尼拉姆利用小干扰 RNA（siRNA）技术来沉默致病基因。公司开发的疗法旨在通过针对一系列罕见和更普遍疾病的潜在遗传驱动因素，提供持久的疾病修正。</p>
</div><p>Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.</p>
<div class="lb-trans"><p>阿尼拉姆已将多种基于 siRNA 的产品推进至商业化，最初使用脂质纳米颗粒递送，最近则采用 GalNAc 结合化学以实现针对肝脏的靶向递送，并通过皮下给药。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Alnylam Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过阿尼拉姆制药</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ALNY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 ALNY 感兴趣的对冲基金持有哪些股票吗？</strong> 请访问 HoldingsChannel.com，获取阿尼拉姆制药公司（NASDAQ:ALNY - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUxOWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ALNY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在阿尼拉姆制药吗？</h2>
</div><p>Before you consider Alnylam Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑阿尼拉姆制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而阿尼拉姆制药并不在名单上。</p>
</div><p>While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然阿尼拉姆制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bronte Capital Management Pty Ltd. Has $15.45 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Market Beat

Perpetual Limited

巴克莱银行

Argenx

布朗特资本管理有限公司在阿里拉姆制药公司持有 1545 万美元的头寸